1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60309C1C70397E51F002587760048D7BE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/heor-leaders-contribute-insights-to-new-research-on-leveraging-outcomes-data?opendocument
18
19opendocument
203.89.204.127
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25Main






54 HEOR Leaders Contribute Insights to New Research On Leveraging Outcomes Data

CHAPEL HILL, N.C., Jan. 13, 2020/PRNewswire/ -- To gain a competitive advantage in today's marketplace, biopharma companies need to demonstrate a new drug’s value proposition and its potential in real-world clinical practice.

This difficult task falls to Health Outcomes groups, one of the most rapidly evolving functions within the pharmaceutical industry.

To inform HEOR leaders on how elite biopharma companies develop successful Health Outcomes (HO) groups, Best Practices, LLC recently completed a new study, "Leveraging Outcomes Data - Operational Roles in Health Economics & Outcomes Research." The 77-page report outlines how organizations are optimizing their HO function to ensure effective access and successful reimbursement.

In particular, this new report illustrates specific ways that the HEOR function drives decision-making and delivers value across medical activities. It also highlights the leading strategies used for effective health outcomes data communication and utilization, stakeholder collaboration, and launch investment timelines for new therapies.

The study found that a key tactic for mature commercial groups was to focus on early-stage HEOR investments (before Phase III) to balance clinical and economic value propositions in drug development.


Key topics addressed in this research include:

  • HEOR involvement and its effectiveness in delivering value
  • Health outcomes data usage and its effectiveness
  • Role of HEOR in health outcomes activities and data collection
  • KPIs to measure success of HEOR
  • Technology and tools used to demonstrate value
  • Challenges and success factors in working with payers

The study engaged 54 executives from 40 leading life sciences companies. Segmentation in this report is based on two areas: Geographic responsibility and HEOR reporting structure.

To learn more about this research, download a complimentary report excerpt at https://www.best-in-class.com/rw97.htm.


ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.